148 related articles for article (PubMed ID: 18826853)
1. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years.
Malluche HH; Siami GA; Swanepoel C; Wang GH; Mawad H; Confer S; Smith M; Pratt RD; Monier-Faugere MC;
Clin Nephrol; 2008 Oct; 70(4):284-95. PubMed ID: 18826853
[TBL] [Abstract][Full Text] [Related]
2. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.
D'Haese PC; Spasovski GB; Sikole A; Hutchison A; Freemont TJ; Sulkova S; Swanepoel C; Pejanovic S; Djukanovic L; Balducci A; Coen G; Sulowicz W; Ferreira A; Torres A; Curic S; Popovic M; Dimkovic N; De Broe ME
Kidney Int Suppl; 2003 Jun; (85):S73-8. PubMed ID: 12753271
[TBL] [Abstract][Full Text] [Related]
3. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up.
Spasovski GB; Sikole A; Gelev S; Masin-Spasovska J; Freemont T; Webster I; Gill M; Jones C; De Broe ME; D'Haese PC
Nephrol Dial Transplant; 2006 Aug; 21(8):2217-24. PubMed ID: 16595583
[TBL] [Abstract][Full Text] [Related]
4. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease.
Freemont AJ; Hoyland JA; Denton J;
Clin Nephrol; 2005 Dec; 64(6):428-37. PubMed ID: 16370155
[TBL] [Abstract][Full Text] [Related]
5. Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia.
Shigematsu T; Tokumoto A; Nakaoka A; Arisaka H
Ther Apher Dial; 2011 Apr; 15(2):176-84. PubMed ID: 21426511
[TBL] [Abstract][Full Text] [Related]
6. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?
Behets GJ; Dams G; Vercauteren SR; Damment SJ; Bouillon R; De Broe ME; D'Haese PC
J Am Soc Nephrol; 2004 Aug; 15(8):2219-28. PubMed ID: 15284308
[TBL] [Abstract][Full Text] [Related]
7. Lanthanum carbonate: a postmarketing observational study of efficacy and safety.
Rombolà G; Londrino F; Corbani V; Falqui V; Ardini M; Zattera T;
J Nephrol; 2012; 25(4):490-6. PubMed ID: 22476966
[TBL] [Abstract][Full Text] [Related]
8. Effects of lanthanum carbonate on bone markers and bone mineral density in incident hemodialysis patients.
Goto K; Goto S; Fujii H; Watanabe K; Kono K; Nishi S
J Bone Miner Metab; 2019 Nov; 37(6):1075-1082. PubMed ID: 31214836
[TBL] [Abstract][Full Text] [Related]
9. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study.
Toida T; Fukudome K; Fujimoto S; Yamada K; Sato Y; Chiyotanda S; Kitamura K
Clin Nephrol; 2012 Sep; 78(3):216-23. PubMed ID: 22874110
[TBL] [Abstract][Full Text] [Related]
10. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
Finn WF; Joy MS;
Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review.
Zhang C; Wen J; Li Z; Fan J
BMC Nephrol; 2013 Oct; 14():226. PubMed ID: 24134531
[TBL] [Abstract][Full Text] [Related]
12. Effects of treatment of renal osteodystrophy on bone histology.
Malluche HH; Mawad H; Monier-Faugere MC
Clin J Am Soc Nephrol; 2008 Nov; 3 Suppl 3(Suppl 3):S157-63. PubMed ID: 18988701
[TBL] [Abstract][Full Text] [Related]
13. Utilization of bone histomorphometry in renal osteodystrophy: demonstration of a new approach using data from a prospective study of lanthanum carbonate.
Freemont T; Malluche HH
Clin Nephrol; 2005 Feb; 63(2):138-45. PubMed ID: 15730056
[TBL] [Abstract][Full Text] [Related]
14. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
15. Effects of switch from sevelamer hydrochloride to lanthanum carbonate on serum K and bone metabolic turnover.
Ota S; Hirose M; Izumiya Y; Ishida Y
Ther Apher Dial; 2013 Apr; 17 Suppl 1():49-53. PubMed ID: 23586513
[TBL] [Abstract][Full Text] [Related]
16. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients.
Ferreira A; Frazão JM; Monier-Faugere MC; Gil C; Galvao J; Oliveira C; Baldaia J; Rodrigues I; Santos C; Ribeiro S; Hoenger RM; Duggal A; Malluche HH;
J Am Soc Nephrol; 2008 Feb; 19(2):405-12. PubMed ID: 18199805
[TBL] [Abstract][Full Text] [Related]
17. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study.
Sprague SM; Ross EA; Nath SD; Zhang P; Pratt RD; Krause R
Clin Nephrol; 2009 Oct; 72(4):252-8. PubMed ID: 19825330
[TBL] [Abstract][Full Text] [Related]
18. Effects of switching from calcium carbonate to lanthanum carbonate on bone mineral metabolism in hemodialysis patients.
Manabe R; Fukami K; Ando R; Sakai K; Kusumoto T; Hazama T; Adachi T; Kaida Y; Nakayama Y; Ueda S; Kohno K; Wada Y; Yamagishi S; Okuda S
Ther Apher Dial; 2013 Apr; 17 Suppl 1():35-40. PubMed ID: 23586511
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial.
Toussaint ND; Lau KK; Polkinghorne KR; Kerr PG
Nephrology (Carlton); 2011 Mar; 16(3):290-8. PubMed ID: 21342323
[TBL] [Abstract][Full Text] [Related]
20. Multicenter study on the long-term (3-year) efficacy of lanthanum carbonate in dialysis patients.
Ando R; Yama S; Ohnishi T; Iwamoto S; Kimura H; Chida Y; Ishida Y; Yamada K; Inagaki Y; Takayama M; Tachibana K; Kikuchi K; Inoue A; Ohtsuka M
Ther Apher Dial; 2014 Jun; 18 Suppl 1():2-8. PubMed ID: 24953759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]